Pharmacist and certified radiopharmacist at Vienna General Hospital (AKH).
Dr. Markus Mitterhauser is a radiopharmaceutical scientist with recognized expertise in theranostics, molecular imaging, and the development and clinical application of modern radiopharmaceuticals for PET imaging and therapy.
He has been affiliated with the Medical University of Vienna for many years, where he is actively involved in both clinical nuclear medicine and scientific research. A particular focus of his work lies in radiopharmacy, quality assurance in nuclear medicine procedures, and the advancement of theranostic concepts.
Dr. Mitterhauser is the author of more than 270 scientific publications and is engaged in national and international research collaborations. His work makes a significant contribution to precise theranostics and the continuous advancement of modern nuclear medicine methods. In addition to his clinical duties and research activities, he is deeply committed to academic teaching at the University of Vienna, the Medical University of Vienna, and various universities of applied sciences, contributing to the training of younger colleagues.
Beyond his clinical and academic work, Dr. Mitterhauser is also directly involved in supporting patients with prostate cancer. In 2020, he founded the initiative PATIO to provide targeted support and guidance for those affected. PATIO aims to improve quality of life in daily living with prostate cancer through collaboration with patients themselves. To further expand these efforts and secure the necessary resources, he established the PATIO association at the end of 2025.
At Theranosticum Vienna, Dr. Mitterhauser contributes his scientific and clinical-pharmaceutical expertise to the careful planning, execution, and interpretation of nuclear medicine examinations. As a pharmacist, he also ensures that therapeutic radiopharmaceuticals are prepared and made available to patients at the highest quality standards.
Memberships
- European Association of Nuclear Medicine (EANM)
- Society of Nuclear Medicine and Molecular Imaging (SNMMI)
- Member of the Scientific Advisory Board of the Helmholtz-Zentrum Dresden-Rossendorf
Languages
- German
- English
Professional Background
Dr. Mitterhauser completed his medical studies at the University of Innsbruck and completed his specialist training in neurology at a leading hospital in Austria.
Publications
- Markus Mitterhauser, Stefan Tögel, Wolfgang Wadsak u. a.
Pre-, Ex- and In-vivo Evaluation of [68Ga]-EDTMP
Nuclear Medicine and Biology, 2007. - Andreas Hahn, Gregor Gryglewski, Lukas Nics, … Markus Mitterhauser, Marcus Hacker, …
Quantification of Task-Specific Glucose Metabolism with Constant Infusion of ^18F-FDG
Journal of Nuclear Medicine, 2016. - Bernhard Grubmüller, Daniela Senn, Gero Kramer, … Markus Mitterhauser, Marcus Hacker, …
Response Assessment Using 68Ga-PSMA Ligand PET in Patients Undergoing 177Lu-PSMA Therapy
– Peer-Reviewed-Studie zur Bewertung der Therapieantwort bei PSMA Radioligandentherapie. - Markus Mitterhauser & Wolfgang Wadsak
Basics and Principles of Radiopharmaceuticals for PET/CT
European Journal of Radiology, 2010. - Georg Zettinig, Markus Mitterhauser, Wolfgang Wadsak u. a.
Positron Emission Tomography Imaging of Adrenal Masses: (18)F-FDG and (11)C-Metomidate
European Journal of Nuclear Medicine and Molecular Imaging, 2004. - Markus Mitterhauser, Daniela Haeusler, Leonhard-Key Mien u. a.
Automatisation and First Evaluation of [18F]FE@SUPPY:2, an Alternative PET-Tracer
The Open Nuclear Medicine Journal, 2009. - Markus Mitterhauser et al.
Labelling of EDTMP (Multibone®) with [111In], [99mTc] and [188Re] Using Different Carriers for Cross Complexation
Applied Radiation and Isotopes, 2004.
“For me, precision comes first. Every step of the examination must be carefully planned and reliably executed so that patients can feel confident and the results are truly reliable.”
Dr. Markus Mitterhauser
We take time for what matters - your care
If you have questions or would like to schedule an appointment, we are here for you.
In a personal consultation, we discuss your concerns in a calm setting and outline the next steps together.
Our team will get back to you promptly and support you competently and reliably - from the first contact through to your therapy appointment.
